How healthcare technology can be improved to treat melanoma

. Is one technology clinically better than another

Advanced malignant melanoma has seven primarily drug treatments. Health technology assessments have been used to compare the effectiveness of each drug. The primary considerations are the overall survival rate, quality of life, cost-effectiveness, adverse side-effects, and the quality of data used to properly ascertain the drug effectiveness (Pike, 2015). The seven drugs subject the HTA are listed below:

a. Cobimetinib

b. Dabrafenib

c. Ipilimumab

d. Nivolumab

e. Pembrolizumab

f. Trametinib

g. Vemurafenib

2. Are there differences in safety profiles of available technology choices?

Yes, there a stark difference between safety profiles. Patients, without treatment have very poor prognosis with survival rates of 12% of men and 25% for women. In cases where treatment of Trametinib was used safety and survival rates increased roughly 40% (Robert, 2015)

3. What is the cost of the technology?

Nivolumab was the most cost-effective treatment costing $24,483 per quality adjusted life year according to the research (Long, 2014). The cost effectiveness of the treatment has declined every year for the past decade as new advances in administration and number of treatments has declined. In 2010, the cost was roughly $37,000 per quality adjusted life year.

4. Who will use the technology?

Those who will use the technology are suffering for incidences of malignant melanoma. The technology can be adopted by patients around the world irrespective of location. The studies conducted focused primarily on Hungary and the European Union.

5. Will the technology result in improved patient outcomes?

Yes, the technology will improve patient outcomes as it relates to survival rate, quality of life and cost-effectiveness of treatments. The most important improvement is related to patient outcomes as the survival rates prior to treatment breakthroughs were very low. As noted above the effectiveness has increase roughly 40%.

6. Health Technology Assessment Topic

My topic will be Melanoma. The focus will be on problem-oriented assessments HTA, and I need to have information on what is Melanoma, diagnosis, and treatment. Melanoma is heavily prevalent in third world countries and in Asia. In particular, it is heavily prevalent in Australia and New Zealand. My topic is predicated on prevention and which treatments can serve these populations in the most cost-effective manner.

7. How Will the Selected Health Technology Assessment Be Important for Your Advanced Practice